RxDoctor Payments Data

Keith Rasmussen, OD

Optometrist · Sioux Falls, SDNPI 1831195759

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Alcon at 29.8% of the total. 2025 is the largest year on record at $569, 3.8 times the $148 reported in 2019.

$1,238in general payments, 2019–2025

Across 55 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$369
  • AbbVie$231
  • Tarsus Pharmaceuticals, Inc.$168
  • Sun Pharmaceutical Industries Inc.$107
  • Novartis$86
  • Johnson & Johnson Surgical Vision, Inc.$53
  • plus $224 from 8 others

What the payments were for

  • Food & beverage$1,238100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,238 in reported general payments places this provider in the 70th percentile of 206 optometrist providers in South Dakota.

See all optometrist providers in South Dakota

Medicare billing

Part B allowed, 2024
$125,039
Medicare patients
496
Services billed
1,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine166$130,069
XiidraLifitegrast97$78,031
Cyclosporine29$14,130
TyrvayaVarenicline Tartrate15$9,616
MieboPerfluorohexyloctane/Pf13$9,595
Lotemax SmLoteprednol Etabonate14$3,689
Prednisolone Acetate74$2,218
MoxifloxacinMoxifloxacin Hcl15$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$231$130,069166 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$16$87,626110 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$24$3,68914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 206 optometrist providers in South Dakota.

Other optometrist in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →